147862-03-1

Basic information

• Product Name: 3-{[(2S)-3-(biphenyl-4-yl)-2-{[(diphenoxyphosphoryl)methyl]amino}propanoyl]amino}propanoic acid (non-preferred name)
• CAS NO: 147862-03-1
• Molecular Formula: C₃₁H₃₁N₂O₆P
• Molecular Weight: 558.5614
• Mol File: 147862-03-1.mol

Chemical Properties

• Boiling Point: 784.9°C at 760 mmHg
• Flash Point: 428.5°C
• Density: 1.267g/cm³
• Vapor Pressure: 5.99E-26mmHg at 25°C
• Refractive Index: 1.604
• CAS DataBase Reference: 3-{[(2S)-3-(biphenyl-4-yl)-2-{[(diphenoxyphosphoryl)methyl]amino}propanoyl]amino}propanoic acid (non-preferred name)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-{[(2S)-3-(biphenyl-4-yl)-2-{[(diphenoxyphosphoryl)methyl]amino}propanoyl]amino}propanoic acid (non-preferred name)(147862-03-1)
• EPA Substance Registry System: 3-{[(2S)-3-(biphenyl-4-yl)-2-{[(diphenoxyphosphoryl)methyl]amino}propanoyl]amino}propanoic acid (non-preferred name)(147862-03-1)

Safety Data

• Hazardous Substances Data: 147862-03-1(Hazardous Substances Data)

Upstream product

• 147862-25-7 1,3,5-tris<(S)-1-(1-O-benzyl-β-alaninyl)-3-(4-biphenylyl)-1-oxo-2-propyl>hexahydro-1,3,5-triazine 
• 147862-02-0 benzyl (S)-N-[2-(diphenylphosphonomethylamino)-3-(4-biphenylyl)-propionyl]-3-aminopropionate 
• 4712-55-4 diphenyl hydrogen phosphite 

Downstream Products

• 147862-27-9 5-indanyl (S)-N-[2-(diphenylphosphonomethylamino)-3-(4-biphenylyl)-propionyl]-3-aminopropionate 
• 147862-05-3 N,N-diethylcarbamoylmethyl (S)-N-[2-(diphenylphosphonomethylamino)-3-(4-biphenylyl)-propionyl]-3-aminopropionate 
• 158894-54-3 3-{(S)-3-Biphenyl-4-yl-2-[(diphenoxy-phosphorylmethyl)-amino]-propionylamino}-propionic acid (diisopropylcarbamoyl)-methyl ester 
• 147862-12-2 3-{(S)-3-Biphenyl-4-yl-2-[(diphenoxy-phosphorylmethyl)-amino]-propionylamino}-propionic acid ethyl ester 

Relevant articles and documents

N-phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors

Inhibitors of the zinc protease neutral endopeptidase (NEP, EC 3.4.24.11) offer significant therapeutic interest as antihypertensives due to their ability to potentiate the biological action of the circulating natriuretic hormone ANF (atrial natriuretic f

Phosphono/biaryl substituted dipetide derivatives

The invention relates to the N-phosphonomethyl-biaryl substituted dipeptide derivatives of formula I STR1 and tetrazole derivatives of the formula Ia STR2 wherein A represents a direct bond, lower alkylene, phenylene or cyclohexylene; m represents 1 or zero, provided that m represents 1 when A is a direct bond; R2 represents hydrogen, hydroxy, lower alkyl, aryl-lower alkyl, C5 -C7 -cycloalkyl-lower alkyl, amino-lower alkyl, hydroxy-lower alkyl, lower alkylthio-lower alkyl, lower alkoxy-lower alkyl, aryl-lower alkylthio-lower alkyl or aryl-lower alkoxy-lower alkyl; biaryl represents phenyl substituted by carbocyclic or heterocyclic aryl; and pharmaceutically acceptable mono-, di- or tri-ester derivatives thereof in which one, two or three of the acidic hydroxy groups of the carboxyl and/or phosphono functional groups are esterified in form of a mono-, di- or tri-pharmaceutically acceptable ester; and pharmaceutically acceptable amide derivatives thereof wherein the carboxyl group is derivatized in form of a pharmaceutically acceptable amide; and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; methods for the preparation of said compounds and for the preparation of intermediates; and methods of treating disorders in mammals which are responsive to the inhibition of neutral endopeptidases by administration of said compounds to mammals in need of such treatment.

Phosphono/biaryl substituted dipeptide derivatives

The invention relates to the N-phosphonomethyl-biaryl substituted dipeptide derivatives of formula I STR1 wherein A represents a direct bond, lower alkylene, phenylene or cyclohexylene; m represents 1 or zero, provided that m represents 1 when A is a direct bond; R2 represents hydrogen, hydroxy, lower alkyl, aryl-lower alkyl, C5 -C7 -cycloalkyl-lower alkyl, amino-lower alkyl, hydroxyl-lower alkyl, lower alkylthio-lower alkyl, lower alkoxy-lower alkyl, aryl-lower alkylthio-lower alkyl or aryl-lower alkoxy-lower alkyl; biaryl represents phenyl substituted by carbocyclic or heterocyclic aryl; and pharmaceutically acceptable mono-, di- or tri-ester derivatives thereof in which one, two or three of the acidic hydroxy groups of the carboxyl and phosphono functional groups are esterified in form of a mono-, di- or tri- pharmaceutically acceptable ester; and pharmaceutically acceptable amide derivatives thereof wherein the carboxyl group is derivatized in form of a pharmaceutically acceptable amide; and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; methods for the preparation of said compounds and for the preparation of intermediates; and methods of treating disorders in mammals which are responsive to the inhibition of neutral endopeptidases by administration of said compounds to mammals in need of such treatment.